News

Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...
Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...
(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.
The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...
Scientists in India are making significant strides in protecting our beloved pets from COVID-19. The ICAR-National Veterinary ...
The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted ...
The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...